PAO Group (PAOG) 주식 개요는 대체 환자 치료법에 중점을 두고 있습니다. 자세히 보기PAOG 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.재무 데이터를 보고하지 않았습니다.의미 있는 시가총액이 없습니다($287K)모든 위험 점검 보기PAOG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0003해당 없음내재 할인율Est. Revenue$PastFuture012016201920222025202620282031Revenue US$1.0Earnings US$0.1AdvancedSet Fair ValueView all narrativesPAO Group, Inc. 경쟁사EcofibreSymbol: OTCPK:EOFB.FMarket cap: US$366.6kAltamira TherapeuticsSymbol: OTCPK:CYTO.FMarket cap: US$641.7kPetros PharmaceuticalsSymbol: OTCPK:PTPIMarket cap: US$269.4kAvenue TherapeuticsSymbol: OTCPK:ATXIMarket cap: US$915.0k가격 이력 및 성과PAO Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.000352주 최고가US$0.000852주 최저가US$0.000001베타01개월 변동50.00%3개월 변동-50.00%1년 변동29,900.00%3년 변동200.00%5년 변동-94.55%IPO 이후 변동-99.90%최근 뉴스 및 업데이트공시 • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.공시 • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.공시 • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.공시 • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.공시 • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.공시 • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.더 많은 업데이트 보기Recent updates공시 • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.공시 • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.공시 • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.공시 • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.공시 • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.공시 • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.주주 수익률PAOGUS PharmaceuticalsUS 시장7D50.0%1.9%-0.8%1Y29,900.0%41.8%27.1%전체 주주 수익률 보기수익률 대 산업: PAOG은 지난 1년 동안 41.8%의 수익을 기록한 US Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: PAOG은 지난 1년 동안 27.1%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is PAOG's price volatile compared to industry and market?PAOG volatilityPAOG Average Weekly Movement59.1%Pharmaceuticals Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%안정적인 주가: PAOG의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: PAOG의 주간 변동성은 지난 1년간 3507%에서 59%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트n/an/aJim DiPrimawww.pao.group는 대체 환자 치료법에 중점을 두고 있습니다. 이 회사는 자회사를 통해 만성 및 말기 환자 치료를 위한 프리미엄 의료용 대마초 제품의 개발, 판매 및 유통에 종사하고 있습니다. 회사는 오하이오주 샌더스키에 본사를 두고 있습니다.더 보기PAO Group, Inc. 기초 지표 요약PAO Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?PAOG 기초 통계시가총액US$286.53k순이익 (TTM)US$0매출 (TTM)n/an/a주가수익비율(P/E)n/a주가매출비율(P/S)PAOG는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표PAOG 손익계산서 (TTM)매출US$0매출원가US$0총이익US$0기타 비용US$0순이익US$0최근 보고된 실적해당 없음다음 실적 발표일해당 없음주당순이익(EPS)0총이익률0.00%순이익률0.00%부채/자본 비율0.0%PAOG의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 02:39종가2026/05/22 00:00수익N/A연간 수익N/A데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PAO Group, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.
공시 • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.
공시 • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
공시 • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.
공시 • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
공시 • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.
공시 • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.
공시 • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.
공시 • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
공시 • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.
공시 • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
공시 • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.
